How to choose between karyotyping, FISH, and microarrays by target resolution? Essential IVD Platform Guide

The fundamental decision between karyotyping, FISH, and microarrays for chromosomal abnormality detection hinges on a single technical variable: the structural resolution your assay demands.
Traditional karyotyping reliably captures whole-chromosome numerical changes (aneuploidies) and large structural aberrations above approximately 4–5 million base pairs (Mb). For anything smaller—such as microdeletions, microduplications, or submicroscopic copy number variants—you must switch to higher-resolution molecular cytogenetic platforms. Fluorescence in situ hybridization (FISH) and chromosomal microarray (CMA) technologies fill that gap, with FISH excelling at targeted, high-resolution interrogation and microarrays providing a genome-wide, simultaneously multi-loci view.

Core Takeaway: Karyotyping is your low-resolution, broad-survey tool for abnormalities >4–5 Mb. FISH gives you targeted, ultra-high resolution down to a few kilobases depending on sample preparation. Microarrays deliver a balanced middle-ground, scanning the entire genome for copy number changes at a resolution typically ranging from tens to hundreds of kilobases. Your choice is a direct function of the pathogenic variant size you need to see.

The Resolution Spectrum: Matching Technology to Variant Size

Every chromosomal diagnostic technology has a clear, physics-driven detection floor. Understanding these boundaries is the first step in selecting the right platform.

Karyotyping: The Macro View

G-banded karyotyping remains the gold standard for visualizing the entire genome in a single assay. It detects:

• Numerical abnormalities: Monosomies, trisomies, and polyploidies.
• Large structural rearrangements: Translocations, inversions, and large deletions or duplications above a resolution limit of 4–5 Mb (though in practice, high-quality banding can sometimes push to 3–4 Mb).

However, its detection limit is set by the optical resolution of the light microscope and the density of chromatin bands. Subtle microdeletion syndromes—like Angelman syndrome (15q11-q13 deletion) or DiGeorge syndrome (22q11.2 deletion)—routinely fall below this threshold. If your target variant is smaller than ~4 Mb, karyotyping alone is insufficient.

Fluorescence In Situ Hybridization (FISH): Pinpoint Precision

FISH bypasses the banding limit by using fluorescently labeled DNA probes that hybridize directly to specific genomic loci. Its resolution depends not on the assay principle itself, but on the physical state of the target DNA in the sample.

• Metaphase Chromosomes: Highly condensed, yielding a resolution of >1 Mb (probes must be at least 1 Mb apart to be distinguished). Used mainly for rough mapping or identifying the chromosome of interest.
• Stretched Metaphase Chromosomes: Mechanically stretched by centrifugation shear, extending the chromatin up to 20-fold and improving resolution to 200–300 kb.
• Interphase Chromosomes: Naturally unpacked in non-dividing cells, allowing discrimination down to about 25 kb (typically resolving markers 100–500 kb apart). This is the workhorse state for clinical microdeletion testing.
• Stretched DNA Fibers: The ultimate FISH resolution, achieving <5 kb, enabling fine-scale mapping of adjacent targets.

This tunable resolution makes FISH ideal for targeted confirmation of small, known abnormalities—like a specific microdeletion—with extreme signal specificity. But it examines only the loci your probes are designed to recognize, not the rest of the genome.

Chromosomal Microarrays (CMA): Genome-Wide, High-Resolution Scanning

Microarray platforms (array-CGH and SNP arrays) measure DNA copy number at thousands to millions of probes simultaneously. They detect copy number variations (CNVs) across the entire genome with a resolution determined by the probe density and spacing.

• Typical clinical arrays offer a backbone resolution that reliably calls gains/losses in the 50–200 kb range, with much higher resolution in clinically relevant targeted regions.
• They can detect submicroscopic deletions and duplications far below the karyotyping threshold but generally do not reach the single-gene or intra-exon level.
• Crucially, microarrays cannot detect balanced rearrangements (e.g., balanced translocations, inversions) because they measure only copy number, not structural position.

Understanding the Trade-offs

No single technology is universally optimal. Each brings constraints that directly impact assay design and clinical sensitivity.

Karyotyping: Broad but Blind

• Strength: A single panoramic view of all chromosomes, detecting balanced rearrangements and complex karyotypes that other methods miss.
• Weakness: Fixed resolution floor around 4 Mb. Covers large territory but at a coarse grain. Culture requirements add time and potential failure rate.
• Assay development implication: If your diagnostic targets include both aneuploidies and large rearrangements, karyotyping is non-negotiable as a foundational screen. But it must be paired with higher-resolution methods for submicroscopic events.

FISH: High-Resolution but Myopic

• Strength: Exceptional spatial resolution, single-cell analysis, and the ability to work on non-dividing interphase cells. Directly confirms the presence or absence of tiny deletions.
• Weakness: Low throughput and locus-limited. You must already suspect the specific region. It's impractical for genome-wide screening.
• Assay development implication: FISH is your confirmatory, targeted tool. Use it when you need to interrogate a known microdeletion locus with clinical certainty, or when dealing with samples where cell division is challenging.

Microarrays: Balanced Power with Blind Spots

• Strength: High-throughput, genome-wide copy number screening at resolutions far beyond karyotyping. Detects thousands of CNVs in a single experiment.
• Weakness: Inability to detect balanced rearrangements, and limited sensitivity for very low-level mosaicism (< 10–15% depending on platform). Resolution is also probe-dependent; large inter-probe gaps can still harbor pathogenic variants.
• Assay development implication: CMA is the modern first-tier test for many constitutional disorders. It replaces karyotyping for copy number screening but should be combined with FISH or sequencing if balanced rearrangements or single-gene resolution is required.

Making the Right Choice for Your Diagnostic Goal

Your technology selection flows directly from the clinical question and the size of the aberration you aim to detect.

• If your primary focus is genome-wide screening for aneuploidies and large rearrangements: Start with karyotyping. It remains unmatched for detecting balanced translocations and gross chromosomal chaos.
• If your primary focus is confirming a known microdeletion or microduplication (typically <3 Mb) with single-cell resolution: Use interphase FISH with locus-specific probes. It gives you a definitive yes/no answer at the specific target site.
• If your primary focus is discovering novel, submicroscopic copy number variants across the entire genome: Choose a chromosomal microarray. It offers the best balance of throughput, resolution, and genome-wide coverage for CNV detection.
• If your target approaches the single-gene or intra-exon level: Even the highest-resolution FISH or densest microarray may fall short. Consider complementing your cytogenomic workup with targeted PCR, MLPA, or sequencing-based methods designed for small variants.

Matching the physical size of the chromosomal lesion to the platform’s resolution capability isn't just a technical nuance—it's the central logic of modern cytogenomic assay design. By making that match explicit, you ensure your assay is both sensitive and clinically actionable.

Summary Table:

Accelerate Your Cytogenomic Assay Development with CamelBio

Selecting the ideal diagnostic platform is only the first step—ensuring consistent, high-performance assay execution requires robust reagents and technical backing.

CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to IVD raw materials, technical services, and consulting—covering every stage from concept to clinic.

• Comprehensive Raw Materials: Reliable, high-purity components tailored for molecular diagnostic assays.
• Expert Technical Consulting: Guidance on platform selection, assay design, and protocol optimization.
• End-to-End Support: Streamline your workflow from initial discovery through regulatory validation.

Ready to optimize your diagnostic assay pipeline? Contact CamelBio Today to collaborate with our technical experts!